Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-blind, Placebo-controlled and Open Label Extension Study to Assess the Efficacy, Safety, and Pharmacokinetic Profile of of ATL1102 in Non-ambulatory Participants With Duchenne Muscular Dystrophy

NCT05938023 is registered in ClinicalTrials.gov with Percheron Therapeutics as lead sponsor.

NCT NCT05938023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05938023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-blind, Placebo-controlled and Open Label Extension Study to Assess the Efficacy, Safety, and Pharmacokinetic Profile of of ATL1102 in Non-ambulatory Participants With Duchenne Muscular Dystrophy
Lead sponsor
Percheron Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
May 18, 2023
Completion date
January 15, 2025
Enrollment
48 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy